Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9573 posts found.

US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit

August 5, 2024 Research and Development GSK, Oncology, Reproductive health, endometrial cancer

PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel (chemotherapy) …
News
Press release

Johnson & Johnson’s MedTech announce orthopaedics receives 501K clearance from FDA for spinal robotics and navigation platform

August 5, 2024 Research and Development 501k clearance, Johnson & Johnson MedTech, Orthopaedics, orthopaedics, robotics, spinal, surgery

Today, the Orthopaedics branch of Johnson & Johnson MedTech, DePuy Synthes, has announced that their surgical robotics system VELYS active …
News

Novo Holdings Invests in Oxford Nanopore Technologies 

August 1, 2024 Research and Development Microbiology, Novo Holdings, Oxford Nanopore Technologies, biopharmacuticals, biotech, data, drug therapies, investment

leading life science investor Novo Holdings, announced a £50m investment in Oxford Nanopore Technologies. Oxford Nanopore Technologies is a leading …
News
handshake

Inizio Engage and Nye Health form a strategic alliance to enhance patient support and outcomes 

August 1, 2024 Research and Development Contraception, Inizio Engage, NHS, Nye Health, alliance, data, patient data, patient experience, support

 Nye Health’s digital platform will be coupled with the patient support experience available at Inizio Engage. The integrated approach will …
News

INDEPENDENT PARSORTIX STUDY HIGHLIGHTS BENEFITS OF COMBINED DNA ANALYSIS IN MELANOMA

August 1, 2024 Medical Communications, Research and Development Angle, Internal Medicine, Oncology, Parsortix, melanoma

Multi-analyte approach has potential to guide personalised cancer care CTC mutation profiles associated with more aggressive disease ANGLE plc. a …
News
Press release

Eisai presents latest findings for lecanemab at Alzheimer’s Association International Conference (AAIC)

July 31, 2024 Research and Development Alzheimers, Conference results, Eisai, Neurology

Clarity AD open-label extension (OLE) data show: three years of continuous lecanemab treatment reduced clinical decline by -0.95 vs expected …
News
Press release

Drug discovery and development partnership announced between Apollo Therapeutics and Oxford University

July 31, 2024 Clinical Research, Medical Communications, Research and Development Apollo Therapeutics, Internal Medicine, Microbiology, drug development, drug discovery, research

Portfolio therapeutics company Apollo Therapeutics has announced earlier this week that it will provide capital and expertise to Oxford University’s …
News

FDA release statement exercising caution around dosing errors associated with compounded injectable semaglutide products

July 31, 2024 Media Relations, Medical Communications, Pharmacovigilance, US Healthcare & Trade Press FDA, Gastrointestinal tract, compunded injectable, dosage, hospitalisation, pharmaceutical, warning

This week, the US Food and Drug Administration (FDA) and have issued warnings regarding dosing errors associated with compounded injectable …
News

AstraZeneca’s AMPLIFY trial interim analysis demonstrates positive results for Calquence plus venetoclax

July 30, 2024 Research and Development AstraZeneca, Haematology, chronic lymphocytic leukaemia, haematology, trial analysis

AstraZeneca has announced positive high-level results from an interim analysis for its AMPLIFY phase 3 trial, combining AstraZeneca’s Calquence (acalabrutinib) …
News

Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI  in combination with MEKTOVI  for the treatment of adult patients with advanced non-small cell lung cancer  NSCLC) with a BRAFV600E mutation

July 29, 2024 Clinical Trial Services BRAF mutation, CHMP, EMA, Oncology, Pierre Fabre Laboratories, colorectal cancer, european studies, non-small cell lung cancer

Pierre Fabre Laboratories has announced a positive opinion from the European Medical Association’s (EMA) Committee for Medicinal Products Human use …
News

CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma

July 29, 2024 Research and Development ADC, CHMP, Merck, Oncology, Urology, keytruda, metastatic urothelial carcinoma, unresectable urothelial carcinoma

Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 therapy, in combination with Padcev …
News

Calliditas Therapeutics announces positive phase 2b data in Primary Biliary Cholangitis trial

July 26, 2024 Research and Development Calliditas, Hepatology, clinical trials, elevated liver stiffness, primary biliary cholangitis

 Calliditas Therapeutics AB today announced that the phase 2b TRANSFORM trial met its primary endpoint. The trial showed statistically significant …
News
alzheimers_brain

AC Immune’s pTau-targeting immunotherapy awarded Fast Track designation by FDA

July 26, 2024 Research and Development AC Immune, Alzheimer's disease, Neurology, clinical trials, fast track designation, immunotherapy, tau protein

Clinical-stage biopharmaceutical company AC Immune announced that the US Food and Drug Administration (FDA) has granted its Alzheimer’s disease (AD) …
News

ViiV Healthcare shares data for two-drug regimen for HIV-1 maintenance therapy

July 23, 2024 Research and Development GSK, HIV, HIV/AIDS, ViiV Healthcare, maintenance therapy

GSK has announced that ViiV Healthcare, a specialist HIV company predominantly owned by GSK with Pfizer and Shionogi as shareholders, …
News

Results from Sanofi’s ALTUVIIIO XTEND-Kids phase 3 trial published in NEJM

July 22, 2024 Research and Development Altuviiio, Haematology, Sanofi, haemophilia

Sanofi has announced that full results from the XTEND-Kids phase 3 study were published in The New England Journal of …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025